La chaîne d'options affiche les données clés des options sur actions de Grace Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Grace Therapeutics..

Grace Therapeutics (NASDAQ:GRCE) Stock, Chaîne d'Options

Grace Therapeutics

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Grace Therapeutics Inc

Investors with a lot of money to spend have taken a bullish stance on Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TEM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 25 uncommon options trades for Tempus AI.
This isn't normal.
The overall sentiment of these big-money traders is split between 64% bullish and 16%, bearish.
Out of all of the special options we uncovered, 8 are puts, for a total amount of $381,921, and 17 are calls, for a total amount of $1,059,960.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $85.0 for Tempus AI over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Tempus AI's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Tempus AI's substantial trades, within a strike price spectrum from $50.0 to $85.0 over the preceding 30 days.
<h3>Tempus AI 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739289638_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.7</td>
<td>$3.3</td>
<td>$3.6</td>
<td>$79.00</td>
<td>$174.6K</td>
<td>5</td>
<td align="right">512</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$15.9</td>
<td>$15.0</td>
<td>$15.18</td>
<td>$60.00</td>
<td>$151.8K</td>
<td>2.5K</td>
<td align="right">107</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$12.7</td>
<td>$12.5</td>
<td>$12.5</td>
<td>$85.00</td>
<td>$125.0K</td>
<td>7</td>
<td align="right">447</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/14/25</td>
<td>$7.7</td>
<td>$6.7</td>
<td>$7.19</td>
<td>$67.00</td>
<td>$122.2K</td>
<td>599</td>
<td align="right">269</td>
</tr>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.0</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$55.00</td>
<td>$77.7K</td>
<td>273</td>
<td align="right">385</td>
</tr>
</tbody>
</table>

<h3>About Tempus AI</h3>
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Following our analysis of the options activities associated with Tempus AI, we pivot to a closer look at the company's own performance.
<h3>Tempus AI's Current Market Status</h3>
<ul>
<li>With a trading volume of 15,942,711, the price of TEM is up by 6.88%, reaching $73.06.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 13 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Tempus AI</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $60.666666666666664.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from TD Cowen lowers its rating to Buy with a new price target of $74. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $56. 
&#x2A; An analyst from Loop Capital has decided to maintain their Buy rating on Tempus AI, which currently sits at a price target of $52. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Tempus AI with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Spotlight on Tempus AI: Analyzing the Surge in Options Activity

<a href="https://www.youtube.com/watch?v=aavRKJYuJkE" title="https://www.youtube.com/watch?v=aavRKJYuJkE">https://www.youtube.com/watch?v=aavRKJYuJkE</a>

Macro Economic Events

News

Economics

Federal Reserve

Powell Says Can't Give An Exact Number, Still Have A Ways To Go; Would Use Quantitative Easing Only When Rates Are At Zero

Whales with a lot of money to spend have taken a noticeably bullish stance on Marvell Tech.
Looking at options history for Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 46% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $523,770 and 9, calls, for a total amount of $741,965.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $72.5 to $150.0 for Marvell Tech over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Marvell Tech's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Marvell Tech's whale activity within a strike price range from $72.5 to $150.0 in the last 30 days. 
<h3>Marvell Tech Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739289633_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$8.75</td>
<td>$8.65</td>
<td>$8.65</td>
<td>$100.00</td>
<td>$173.8K</td>
<td>1.3K</td>
<td align="right">201</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$3.7</td>
<td>$3.15</td>
<td>$3.2</td>
<td>$109.00</td>
<td>$155.2K</td>
<td>164</td>
<td align="right">500</td>
</tr>
<tr>
<td>MRVL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$15.55</td>
<td>$15.4</td>
<td>$15.4</td>
<td>$115.00</td>
<td>$154.0K</td>
<td>623</td>
<td align="right">401</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$23.75</td>
<td>$22.9</td>
<td>$22.95</td>
<td>$115.00</td>
<td>$114.7K</td>
<td>745</td>
<td align="right">104</td>
</tr>
<tr>
<td>MRVL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$23.1</td>
<td>$22.85</td>
<td>$22.85</td>
<td>$115.00</td>
<td>$114.2K</td>
<td>745</td>
<td align="right">54</td>
</tr>
</tbody>
</table>

<h3>About Marvell Tech</h3>
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.
In light of the recent options history for Marvell Tech, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Marvell Tech</h3>
<ul>
<li>Trading volume stands at 2,401,878, with MRVL's price down by -1.03%, positioned at $111.64.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 22 days.</li>
</ul>
<h3>Professional Analyst Ratings for Marvell Tech</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $134.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Marvell Tech, targeting a price of $135. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Marvell Tech, targeting a price of $113. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Marvell Tech, which currently sits at a price target of $150. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Marvell Tech, targeting a price of $140. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Marvell Tech, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

MRVL

A Closer Look at Marvell Tech's Options Market Dynamics

Whales with a lot of money to spend have taken a noticeably bullish stance on Palantir Technologies.
Looking at options history for Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) we detected 56 trades.
If we consider the specifics of each trade, it is accurate to state that 51% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 15 are puts, for a total amount of $631,534 and 41, calls, for a total amount of $2,033,681.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $67.5 to $145.0 for Palantir Technologies during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Palantir Technologies's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Palantir Technologies's whale activity within a strike price range from $67.5 to $145.0 in the last 30 days. 
<h3>Palantir Technologies 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739289627_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.45</td>
<td>$117.00</td>
<td>$144.2K</td>
<td>4.3K</td>
<td>5.8K</td>
</tr>
<tr>
<td>PLTR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$17.35</td>
<td>$17.0</td>
<td>$17.35</td>
<td>$130.00</td>
<td>$140.5K</td>
<td>1.0K</td>
<td>81</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.82</td>
<td>$2.7</td>
<td>$2.76</td>
<td>$125.00</td>
<td>$136.4K</td>
<td>4.2K</td>
<td>957</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$118.00</td>
<td>$133.2K</td>
<td>4.5K</td>
<td>531</td>
</tr>
<tr>
<td>PLTR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$10.15</td>
<td>$9.9</td>
<td>$10.15</td>
<td>$110.00</td>
<td>$101.5K</td>
<td>7.8K</td>
<td>289</td>
</tr>
</tbody>
</table>

<h3>About Palantir Technologies</h3>
Palantir is an analytical software company that focuses on leveraging data to create efficiencies in its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The Denver-based company was founded in 2003 and went public in 2020.
Following our analysis of the options activities associated with Palantir Technologies, we pivot to a closer look at the company's own performance.
<h3>Palantir Technologies's Current Market Status</h3>
<ul>
<li>Trading volume stands at 39,015,039, with PLTR's price down by -0.82%, positioned at $115.69.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 83 days.</li>
</ul>
<h3>What The Experts Say On Palantir Technologies</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $93.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Palantir Technologies, targeting a price of $110. 
&#x2A; Consistent in their evaluation, an analyst from Cantor Fitzgerald keeps a Neutral rating on Palantir Technologies with a target price of $98. 
&#x2A; An analyst from Baird persists with their Neutral rating on Palantir Technologies, maintaining a target price of $100. 
&#x2A; Maintaining their stance, an analyst from Northland Capital Markets continues to hold a Market Perform rating for Palantir Technologies, targeting a price of $80. 
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Underperform rating on Palantir Technologies with a target price of $80. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Palantir Technologies options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

PLTR

Behind the Scenes of Palantir Technologies's Latest Options Trends

Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) has outperformed the market over the past 10 years by 1.49% on an annualized basis producing an average annual return of 12.62%. Currently, Cboe Global Markets has a market capitalization of $21.51 billion. 
Buying $100 In CBOE: If an investor had bought $100 of CBOE stock 10 years ago, it would be worth $328.22 today based on a price of $205.48 for CBOE at the time of writing.
<h3>Cboe Global Markets's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739289621_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

CBOE

Here's How Much You Would Have Made Owning Cboe Global Markets Stock In The Last 10 Years

Fed Chair Powell Says Reserves Are Still Abundant; Shrinking Balance Sheet Is Ongoing

Rosenblatt analyst Steve Frankel maintains Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Buy and lowers the price target from $16 to $12.

Price Target

Analyst Ratings

HLIT

Rosenblatt Maintains Buy on Harmonic, Lowers Price Target to $12

JMP Securities analyst Reni Benjamin reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Market Perform to Market Perform.

Reiteration

INCY

JMP Securities Reiterates Market Perform on Incyteto Market Perform

Government

Politics

General

U.S. Needs To Spend More On Defense Than It Did Under The Biden Administration; U.S. Not Sending Troops Into Ukraine

Jones Trading analyst Soumit Roy upgrades IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) from Hold to Buy and announces $1.2 price target.

Upgrades

INAB

Jones Trading Upgrades IN8bio to Buy, Announces $1.2 Price Target

Fed Chair Powell Says Stand By Previous Comments That Countries That Have Free Trade Grow Faster; Standard Case For Free Trade Still Makes Sense, But Didnt Work That Well When Have One Large Country That Didnt Play By The Rules; Not For Fed To Comment On Tariff Policy; Clearly Not Allowed Under The Law For President To Remove A Fed Board Member

JMP Securities analyst Roy Buchanan maintains Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) with a Market Outperform and lowers the price target from $7 to $4.

ESPR

JMP Securities Maintains Market Outperform on Esperion Therapeutics, Lowers Price Target to $4

Marriott International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) shares <a href="https://www.benzinga.com/movers">are trading lower</a> after the company&#8217;s fourth-quarter FY24 earnings and outlook.
The company reported first-quarter FY24 sales growth of 5.5% year-on-year to $6.429 billion, beating the analyst consensus <a href="https://www.benzinga.com/pressreleases/25/02/n43618868/marriott-international-reports-fourth-quarter-and-full-year-2024-results">estimate of $6.379 billion</a>.
Comparable systemwide constant dollar RevPAR increased 5% worldwide, 4.1% in the U.S. &amp; Canada, and 7.2% in international markets, compared to the fourth-quarter FY23.
With gross room additions of over 123,000 in 2024, net rooms grew 6.8% from year-end 2023
Total expenses declined 6% Y/Y to $5.7 billion. Adjusted EBITDA for the quarter was $1.28 billion versus $1.19 billion a year ago.
Operating margin for the quarter remained flat Y/Y to 11.7%, with operating income increasing 5% to $752 billion.
Adjusted EPS of $2.45 <a href="https://www.benzinga.com/earnings">beat the consensus</a> estimate of $2.38.
The company added about 109,000 rooms globally during the year 2024. Marriott held $0.4 billion in cash and equivalents as of March 31, 2024.
In fourth-quarter, Marriott repurchased 2.0 million shares of common stock for $0.5 billion. The company returned over&nbsp;$4.4 billion&nbsp;to shareholders through dividends and share repurchases in 2024.
Outlook: Marriott sees FY25 adjusted EPS of $9.82 &#8211; $10.19 versus the $10.65 estimate and RevPAR growth of 2% &#8211; 4%.
The company expects first-quarter adjusted EPS of $2.20-$2.23 against an estimate of $2.37 and RevPAR growth of 3% &#8211; 4%.
Price Action: MAR shares are trading lower by 4.3% at $291.30 at last check Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/02/43593007/rivian-commercial-van-now-available-for-fleets-nationwide-in-us">Rivian Commercial Van Now Available For Fleets Nationwide In US</a></li>
</ul>
Photo by gerd-harder via Shutterstock.

Earnings

Movers

Marriott Tops Q4 Estimates As 2025 Outlook Pressures Stock

Goldman Sachs analyst Toshiya Hari maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Buy and lowers the price target from $77 to $64.

Goldman Sachs Maintains Buy on ON Semiconductor, Lowers Price Target to $64

Goldman Sachs analyst Kash Rangan maintains Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Buy and raises the price target from $350 to $400.

MNDY

Goldman Sachs Maintains Buy on Monday.Com, Raises Price Target to $400

Maxim Group analyst Anthony Vendetti maintains Hain Celestial Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) with a Buy and lowers the price target from $15 to $10.

HAIN

Maxim Group Maintains Buy on Hain Celestial Group, Lowers Price Target to $10

On Tuesday, Lipella Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shared topline an analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43617254/lipella-pharmaceuticals-reports-positive-topline-phase-2a-results-for-lp-310-in-the-treatment-of-o" rel="noreferrer noopener">treat oral lichen planus (OLP)</a>.
LP-310 demonstrated a strong safety profile, with no product-related serious adverse events (SAEs) or patient dropouts.
The trial showed statistically significant improvements across multiple patient-reported and investigator-measured efficacy endpoints at weeks 1, 4, and 6.
LP-310 is the only oral rinse topical treatment currently in development for OLP.
Affecting about 6 million Americans, OLP is a chronic inflammatory condition that targets mucous membranes in the mouth, which can cause pain and make eating, drinking, and even speaking uncomfortable.
Characterized by symptoms such as burning pain, white patches, swollen tissue and open sores, OLP has no FDA-approved therapies.
In the first cohort, eight participants received a twice-daily dose of 0.25 mg of LP-310. Follow-up visits occurred at one and four weeks and two weeks post-treatment.
The trial showed significant improvements across multiple efficacy endpoints while suggesting the safety and tolerability of LP-10 in adult patients with symptomatic OLP at the 0.25 mg/10 mL dose.
The trial has progressed to the next higher dose cohort of 0.5 mg/10 mL.
Pharmacokinetic analysis showed that tacrolimus blood levels were undetectable or minimal in all patients, underscoring LP-310&#8217;s potential to deliver localized benefits without systemic toxicity.
Lipella continues to recruit for the trial, with plans to activate additional sites and complete the trial by mid-2025.
The company is preparing for key milestones, including submitting a Phase 2b trial investigational new drug application and a Breakthrough Therapy designation request to the FDA in the second half of 2025.
The second cohort of the Phase 2a study is currently dosing, and topline data is expected in the first half of 2025.
Last week, the FDA granted approval for an Expanded Access Program for LP-310 for OLP. The program allows patients to access treatments outside of a clinical trial that has yet to be <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43522207/lipella-pharmaceuticals-granted-fda-approval-for-expanded-access-program-for-lp-310-in-oral-lichen" rel="noreferrer noopener">approved by the FDA</a>.
Price Action: LIPO stock is up 38.80% at $4.24 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43623967/globalfoundries-beats-q4-estimates-margins-shrink-935-million-impairment-charge" target="_blank" rel="noreferrer noopener">GlobalFoundries Q4 Earnings: Revenue And EPS Beat, Margins Shrink, Revenue Outlook Disappoints Street</a></li>
</ul>

Biotech

Health Care

LIPO

Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes

Goldman Sachs analyst Kate McShane maintains Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) with a Neutral and lowers the price target from $4 to $3.

LESL

Goldman Sachs Maintains Neutral on Leslies, Lowers Price Target to $3

Shares of automotive lidar technology provider Hesai Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) are<a href="https://www.benzinga.com/movers"> trading higher on Tuesday</a>.
The company has entered into an enhanced collaboration with Chinese EV maker BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>), with plans to supply lidar for <a href="https://www.benzinga.com/pressreleases/25/02/n43617334/hesai-and-byd-supercharge-partnership-10-lidar-equipped-models-to-enter-mass-production-in-2025">more than 10 of BYD's models</a>.
These vehicles are slated for mass production in 2025, highlighting the growing role of lidar technology in the evolution of advanced driver assistance systems (ADAS) within the automotive sector.
In 2024, BYD surpassed its domestic rivals by <a href="https://www.benzinga.com/25/02/43427393/tesla-rival-byd-marks-475-growth-in-january-passenger-vehicle-sales-driven-by-popularity-of-plug-in-hybrid-evs">selling more than 4 million</a> vehicles featuring intelligent driving technology.
The company also announced that every model would be equipped with <a href="https://www.benzinga.com/tech/25/02/43617347/xpeng-geely-shares-fall-after-byd-launches-advanced-driver-assistance-features-on-car-priced-below-10000">&#8220;God&#8217;s Eye,&#8221; its next-generation ADAS</a>, providing advanced safety and driver-assistance features to more customers. 
Related Read: <a href="https://www.benzinga.com/news/25/02/43593007/rivian-commercial-van-now-available-for-fleets-nationwide-in-us">Rivian Commercial Van Now Available For Fleets Nationwide In US</a>
Lidar technology will be vital for these systems, especially for vehicles using navigation on autopilot (NOA) for both urban and highway driving.
In 2024, lidar installations in vehicles exceeded 1.5 million units in China, more than doubling the figure from 2023. Also, Hesai became the first lidar maker to ship over 100,000 units in a single month in December 2024.
Hesai anticipates surpassing 2 million units in annual production capacity by 2025. The company has secured more than 100 design wins with 22 automotive OEMs, including well-known brands like Chery, Great Wall Motors, and Changan.
Hesai&#8217;s newest product, the ATX lidar, is scheduled for mass production in the first quarter of 2025. This lidar system is aimed at improving assisted driving capabilities across a broad range of vehicles.
Price Action: Hesai shares are trading higher by 8.78% at $18.59 at the last check Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43566749/spire-global-lands-72m-contract-for-canadian-wildfire-detection-stock-jumps">Spire Global Lands ~$50M Contract For Canadian Wildfire Detection</a></li>
</ul>
Image: Shutterstock

BYDDF

BYDDY

HSAI

Hesai's Lidar Takes On Bigger Role In BYD's 'God's Eye' Advanced Driver Assistance

Maxim Group analyst Allen Klee maintains Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) with a Buy and raises the price target from $13 to $14.

MITK

Maxim Group Maintains Buy on Mitek Systems, Raises Price Target to $14

Grace Therapeutics GAAP EPS of -$0.30 beats by $0.06

Acasti Pharma, Inc. ( ($GRCE) ) has released its Q2 earnings. Here is a breakdown of the information Acasti Pharma, Inc. presented to its investors...

Grace Therapeutics Reports Steady Progress and Financials

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Grace Therapeutics (GRCE – Research Report). The compa...

Craig-Hallum Reaffirms Their Buy Rating on Grace Therapeutics (GRCE)

Grace Therapeutics (GRCE) will be participating in the mid-year clinical meeting of the American Society of Health-System Pharmacists to be held De...

Grace Therapeutics to exhibit at ASHP Conference

Grace therapeutics announces private placement financing of $30 million

Grace Therapeutics (GRCE) announced that its Phase 3 STRIVE-ON safety trial met its primary endpoint and provides evidence of clinical benefit when...

Grace Therapeutics announces results from Phase 3 STRIVE-ON trial

Grace Therapeutics meets main goal in late stage trial for its aneurysmal SAH treatment

GRCE

Press Releases

Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024

Grace Therapeutics Announces Second Fiscal Quarter 2025  Financial Results, Provides Business Update

Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Financing

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

ACST

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

AN2 Therapeutics

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Context Therapeutics

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Impact BioMedical

IGC Pharma

Opus Genetics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Marinus Pharmaceuticals, Inc. - Common Stock

Marinus Pharma

NRX Pharmaceuticals

OptiNose

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

SCYNEXIS

Traws Pharma

Verrica Pharmaceuticals Inc. - Common Stock

Comments

Grace Therapeutics

Grace Therapeutics (GRCE) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL